The present invention relates to a compound comprising at least one phosphepine ring and having the phosphorus atom of the phosphepine ring substituted with at least one monovalent substituent R, a semiconducting material comprising the compound, and electronic device comprising the semiconducting material.

The present disclosure provides a composition comprising at least one compound selected from the group consisting of Compound 1, Compound 2, and combinations thereof, as shown below, and described herein: wherein, for Compound 1 and Compound 2, independently, R.sub.1 and R.sub.2 each independently is selected from the group consisting of hydrogen, a substituted alkyl, an unsubstituted alkyl, a substituted heteroalkyl, an unsubstituted heteroalkyl, a substituted aryl, an unsubstituted aryl, a substituted heteroaryl and an unsubstituted heteroaryl; wherein, for Compound 1 and Compound 2, independently, the Component A is selected from the group consisting of Group a) through Group h): wherein Group a) through Group h) are described herein.

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.

A heterocyclic compound and an organic light-emitting device including the same are provided. The organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer disposed between the first electrode and the second electrode, where the organic layer may include an emission layer and at least one of the heterocyclic compound described above.

An acetylacetone derivative is useful for capturing a metal element by complexation. A convenient and very versatile synthesis method can be used to synthesize the derivative. The derivative can have the following General Formula:

##STR00001##

Provided herein are inhibitors of TNF?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF? inhibitory compounds for the treatment of diseases or disorders.

The present invention covers phosphorus derivatives of general formula (I), in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, X.sub.1, X.sub.2, X.sub.3, X.sub.4 and Y are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, especially diseases associated with SOS1, as a sole agent or in combination with other active ingredients.

##STR00001##

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

A condensed cyclic compound and an organic light-emitting device, the compound being represented by Formula 1:

##STR00001##